No Data
No Data
No Data
Allergy Partners Announces Collaboration With Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] Directly to Patients
Collaboration strengthens patient access to PALFORZIA through Allergy Partners' national network of specialty practices Children and teenagers aged 4 through 17 years with a confirmed diagnosis of pea
Global Food Allergy Market Report to 2032 - Featuring Aimmune Therapeutics, Novartis Pharmaceuticals and DBV Technologies Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Food Allergy - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth under
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
BASEL, Switzerland & CAMBRIDGE, Mass. & HORSHOLM, Denmark--(BUSINESS WIRE)--Bacthera, a specialized contract development and manufacturing organization (CDMO), and Seres Therapeutics, a leadin
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globa
Press Release: Nestle announces results of tender offer for Aimmune Therapeutics, Inc.
Press Release: Nestle announces results of tender offer for Aimmune Therapeutics, Inc. Nestle announces results of tender offer for Aimmune Therapeutics,Inc. PR Newswire VEVEY, Switzerland, Oct. 13
Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary
*DJ Nestle Now Has Around 84% of Aimmune Therapeutics Shares (MORE TO FOLLOW) Dow Jones Newswires October 13, 2020 01:18 ET (05:18 GMT) *DJ Nestle's Subsidiary SPN MergerSub Offered $34.5 for
No Data